Moore, Kathleen http://orcid.org/0000-0002-5803-0718
Chan, John K.
Secord, Angeles Alvarez
Patel, Manish R.
Callahan, Timothy
Guo, Wei
Zhang, Zhi-Yi
Funding for this research was provided by:
Tesaro
Article History
Received: 12 December 2018
Accepted: 9 January 2019
First Online: 24 January 2019
Compliance with ethical standards
:
: K.M. has served on the advisory borads of and received honoraria from AstraZeneca, Advaxis, Clovis, Genentech/Roche, Immunogen, VBL Therapeutics, Janssen, Tesaro, Merck, Aravive, and OncoMed; K.M. also serves as the USA PI for the Tesaro-sponsored FIRST study using niraparib in front-line ovarian cancer and serves as the national PI for the niraparib study QUADRA. J.K.C. has received honoraria for a consulting role from Tesaro, Acerta, Aravive, Biodesix, Clovis, Janssen/Johnson & Johnson, Oxigen/Mateon, Roche/Genentech, and AstraZeneca, has received honoraria for lectures including speakers’ bureaus from AstraZeneca, Clovis, Merck, Roche/Genentech, and Tesaro. A.S.S. has received grants from AbbVie, Amgen, Astellas Pharma Inc., Astex Pharmaceuticals Inc., AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Endocyte, Exelixis, Incyte, Merck, PharmaMar, Prima Biomed, Roche/Genentech, TapImmune, and honoraria for advisory boards from Tesaro, Alexion, Aravive, Astex, AstraZeneca, Boehringer Ingelheim, Clovis, Janssen/Johnson & Johnson, Merck, Mersano, Myriad, Oncoquest, Precision Therapeutics, and Roche/Genentech. M.R.P. has nothing to disclose. T.C. is an employee of BioTel Research. W.G. and Z.Y.Z. employees of Tesaro, Inc and own stock/have other ownership with Tesaro. Medical writing and copyediting support, funded by TESARO, Inc. and coordinated by Hemant Vyas, PhD, of TESARO, Inc, was provided by Swati Ghatpande, PhD, and Ann Marcos, MA, ELS, of Team 9 Science, LLC (Vaniam Group LLC).